List of works by Xavier Leleu

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

scientific article

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study

scientific article published on 01 April 2019

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

scientific article published on 21 November 2016

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis

scientific article

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

scientific article

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

scientific article

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders

scientific article published on May 2006

Carfilzomib Weekly 20/56mg/m , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

scientific article published on 25 November 2018

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

scientific article

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

scientific article

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

scientific article published on November 2006

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

scientific article

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

scientific article published on 3 March 2008

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo

scientific article published on 8 April 2013

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

scientific article published on 28 October 2020

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article

Emerging drugs in multiple myeloma

scientific article published on March 2007

Front line treatment of elderly multiple myeloma in the era of novel agents

scientific article published on 13 July 2009

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

scientific article published on 14 July 2014

Global epigenetic regulation of microRNAs in multiple myeloma

scientific article

HLA-G and lymphoproliferative disorders

scientific article published on October 2003

High-throughput genomic analysis in Waldenström's macroglobulinemia

scientific article published on February 2011

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

scientific article

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

scientific article

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

scientific article published on 26 December 2015

Initial treatment of transplant-ineligible patients in multiple myeloma

scientific article

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease

scientific article published on 20 May 2013

Longitudinal clonal architecture of acute myeloid leukemia with NPM1 driver insertion, early TET2 mutations and secondary e6a2 BCR-ABL1 rearrangement

scientific article published on 20 February 2020

Low-dose biplanar skeletal survey versus digital skeletal survey in multiple myeloma

scientific article published on 20 March 2013

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

scientific article published on April 2007

Melflufen for relapsed and refractory multiple myeloma

scientific article published on 14 September 2020

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

scientific article published on 28 April 2009

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

scientific article

Multiple myeloma: the puzzle is finally completed

scientific article

Novel agents in Waldenstrom Macroglobulinemia

scientific article

Novel therapeutic agents in Waldenström's macroglobulinemia

scientific article

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

scientific article published on 11 March 2014

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 04 May 2018

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

scientific article published on 17 March 2015

Pomalidomide for multiple myeloma

scientific article published on 30 September 2014

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

scientific article published on 9 January 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

scientific article

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

scientific article

Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score

scientific article published on 06 November 2019

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

scientific article

Proteomics analysis in post-transplant lymphoproliferative disorders

scientific article

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

scientific article

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

scientific article

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia

scientific article

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

scientific article

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia

scientific article

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

scientific article

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia

scientific article

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

scientific article

Targeted therapies in Waldenström macroglobulinemia

scientific article

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

scientific article published on February 2008

Targeting NF-kappaB in Waldenstrom macroglobulinemia

scientific article

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

scientific article published on July 2007

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

scientific article (publication date: 15 December 2007)

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

scientific article published on 26 February 2016

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

scientific article published on 3 June 2008

The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia

scientific article

The translocation t(4;14) can be present only in minor subclones in multiple myeloma

scientific article published on 15 July 2013

Thrombosis in myeloma treated with IMiDs

scientific article published on October 2012

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

scientific article

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

scientific article

Update on therapeutic options in Waldenström macroglobulinemia

scientific article

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

scientific article published on 11 June 2012

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients

scientific article

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

scientific article

Waldenstrom macroglobulinemia

scientific article

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia

scientific article

Paulina is supported by:

About Paulina

Help